Ideaya Biosciences Inc (NASDAQ: IDYA) kicked off on Friday, down -5.58% from the previous trading day, before settling in for the closing price of $42.46. Over the past 52 weeks, IDYA has traded in a range of $21.22-$47.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 14.24% over the past five years. While this was happening, its average annual earnings per share was recorded -11.17%. With a float of $75.07 million, this company’s outstanding shares have now reached $84.04 million.
Let’s look at the performance matrix of the company that is accounted for 124 employees.
Ideaya Biosciences Inc (IDYA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ideaya Biosciences Inc is 10.68%, while institutional ownership is 88.30%. The most recent insider transaction that took place on May 29 ’24, was worth 1,032,884. In this transaction Chief Scientific Officer of this company sold 28,500 shares at a rate of $36.24, taking the stock ownership to the 0 shares. Before that another transaction happened on May 16 ’24, when Company’s President and CEO sold 34,433 for $41.81, making the entire transaction worth $1,439,754. This insider now owns 677,887 shares in total.
Ideaya Biosciences Inc (IDYA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.5 earnings per share (EPS), higher than consensus estimate (set at -0.56) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.17% per share during the next fiscal year.
Ideaya Biosciences Inc (NASDAQ: IDYA) Trading Performance Indicators
Take a look at Ideaya Biosciences Inc’s (IDYA) current performance indicators. Last quarter, stock had a quick ratio of 28.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 217.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Ideaya Biosciences Inc (IDYA)
Ideaya Biosciences Inc (NASDAQ: IDYA) saw its 5-day average volume 0.73 million, a negative change from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 45.20%. Additionally, its Average True Range was 2.03.
During the past 100 days, Ideaya Biosciences Inc’s (IDYA) raw stochastic average was set at 53.50%, which indicates a significant increase from 22.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.83% in the past 14 days, which was lower than the 47.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.75, while its 200-day Moving Average is $38.36. Nevertheless, the first resistance level for the watch stands at $41.18 in the near term. At $42.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $43.45. If the price goes on to break the first support level at $38.91, it is likely to go to the next support level at $37.72. Assuming the price breaks the second support level, the third support level stands at $36.63.
Ideaya Biosciences Inc (NASDAQ: IDYA) Key Stats
The company with the Market Capitalisation of 3.37 billion has total of 75,687K Shares Outstanding. Its annual sales at the moment are 23,390 K in contrast with the sum of -112,960 K annual income. Company’s last quarter sales were recorded 3,920 K and last quarter income was -33,950 K.
